HCP Connect Contributor
Dr. Aditi Kulkarni
Dr. Aditi Kulkarni contributes neurology drug update coverage for HCP Connect, with emphasis on source-verified therapeutic developments and practical clinical context for US-licensed practitioners. This profile links the author's recent clinical coverage, specialty focus, and professional contributor metadata in one place.
Recent Drug Updates
16 total
Neurology
FDA Review of Tolebrutinib: Nonrelapsing Secondary Progressive MS Treatment
Tolebrutinib reduces disability progression in nonrelapsing secondary progressive MS by 30% in phase 3 trial.
Neurology
FDA Approves GTx-104 for Aneurysmal Subarachnoid Hemorrhage: 19% Hypotension Reduction in STRIVE-ON Trial
GTx-104 approved for aneurysmal subarachnoid hemorrhage: 19% hypotension reduction in STRIVE-ON trial.
Neurology
FDA Approves Auvelity for Alzheimer Disease Agitation: 73% Relapse Reduction in ACCORD-2 Trial
FDA approves Auvelity for Alzheimer disease agitation: 73% relapse reduction in ACCORD-2 trial.
Neurology
Ionis Submits NDA for Zilganersen: Antisense Oligonucleotide for Alexander Disease
Ionis submits NDA for Zilganersen targeting Alexander disease, showing a 50% reduction in GFAP levels in clinical trials.
Neurology
FDA Approves Tavapadon for Parkinson's Disease: Improved Motor Control in TEMPO Trials
FDA approves Tavapadon for Parkinson's disease, showing 30% motor symptom reduction in TEMPO trials.
Neurology
FDA Submission of CNM-Au8 for ALS: NfL Surrogate Endpoint Considered
Clene Nanoscience's CNM-Au8 for ALS shows promise with NfL as a surrogate endpoint, aiming for FDA approval.
Neurology
FDA Approves Atogepant for Episodic Migraine Prevention: 50% Reduction in Migraine Days
Atogepant approved for episodic migraine prevention: 50% reduction in migraine days in ADVANCE trial.
Neurology
FDA Approves Lecanemab for Alzheimer: 27% Cognitive Decline Reduction
FDA approves lecanemab for Alzheimer: 27% cognitive decline reduction in early-stage patients, highlighting new treatment options.
Neurology
CGRP Inhibitors for Migraine Prevention: Comparing Erenumab, Fremanezumab, Atogepant, and Rimegepant
CGRP inhibitors for migraine prevention: comparing erenumab, fremanezumab, atogepant, and rimegepant for optimal patient outcomes.
Medical Research
Type 2 Diabetes Linked to Faster Chronic Disease Onset
New research reveals type 2 diabetes accelerates development of multiple chronic diseases, particularly in middle-aged adults, impacting patient outcomes and treatment plans.
Medical Research
Emotional Eaters Less Likely to Lose Weight on GLP-1 Therapy
Research reveals individuals who overeat for emotional reasons may have reduced weight loss success with GLP-1 receptor agonists like Ozempic.
Healthcare Business
Reduce Mental Fatigue in Hearing Loss Patients by 30%
Discover how addressing hearing loss can improve mental health outcomes, reducing social isolation, anxiety, and depression in patients.
Neurology
Boost Neurology Dept Efficiency with Effective Vice Chair Roles
Discover how evolving vice chair responsibilities can enhance neurology department leadership, faculty engagement, and alignment with institutional goals.
Health Information
Accurate RA Diagnosis in Less Time
Learn how lab tests and imaging help doctors diagnose rheumatoid arthritis quickly and accurately, reducing diagnostic time and improving patient outcomes.
Medical Devices
Boost Breast Cancer Survival Rates with Latest Treatments
Discover how advances in breast cancer treatment are improving patient outcomes and survival rates, offering new hope for individuals diagnosed with the disease.
Medical Research
FDA May Drop Expert Reviews, Impacting Drug Approval
Proposed FDA policy change could reduce public scrutiny of new drug approvals, what it means for physicians and patient care decisions.